Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: Recent advances and emerging therapies by Allison M. Bock, Narendranath Epperla

Get full text

Cardiovascular toxicities associated with novel cellular immune therapies by Malak Munir, Ahmed Sayed, Daniel Addison, Narendranath Epperla

Get full text

Association of CAR-T approval on outcomes in patients with diffuse large B-cell lymphoma at the population level in the United States by John L. Vaughn, Angela Ramdhanny, Malak Munir, Sravani Rimmalapudi, Narendranath Epperla

Get full text

Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma by Narendranath Epperla, Melanie Lucero, Tom Bailey, Laura Mirams, Jolenta Cheung, Mona Amet, Gary Milligan, Lei Chen

Get full text

Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma by Narendranath Epperla, Loretta J. Nastoupil, Bruce Feinberg, John Galvin, Prathamesh Pathak, Theresa Amoloja, Danielle Gentile, Kim Saverno

Get full text

Impact of diagnosis to treatment interval on outcomes in patients with newly diagnosed marginal zone lymphoma - a US multisite study by Narendranath Epperla, Geoffrey Shouse, Natalie S. Grover, Pallawi Torka, Kaitlin Annunzio, Marcus Watkins, Andrea Anampa-Guzmán, Beth Christian, Colin Thomas, Stefan K. Barta, Praveen Ramakrishnan Geethakumari, Reem Karmali, Nancy L. Bartlett, Adam J. Olszewski

Get full text

Impact of circulating lymphoma cells at diagnosis on outcomes in patients with newly diagnosed de novo diffuse large B-cell lymphoma by Sayan Mullick Chowdhury, Subodh Bhatta, Timothy J. Voorhees, Kaitlin Annunzio, David A. Bond, Yazeed Sawalha, Audrey Sigmund, Walter Hanel, Lalit Sehgal, Lapo Alinari, Robert Baiocchi, Kami Maddocks, Beth Christian, Dan Jones, Narendranath Epperla

Get full text

Siltuximab for chimeric antigen receptor T-cell therapy–related CRS and ICANS: a multicenter retrospective analysis by Amneet Bajwa, Qiuhong Zhao, Marcus Geer, Chenyu Lin, James Westholder, Joseph Maakaron, Monalisa Ghosh, David Frame, Ahmed Galal, Justin Tossey, Nausheen Ahmed, Evandro Bezerra, Nathan Denlinger, Marcos de Lima, Narendranath Epperla, Paolo Caimi, Timothy Voorhees

Get full text

Evaluation of Ki-67 expression and large cell content as prognostic markers in MZL: a multicenter cohort study by Natalie S. Grover, Kaitlin Annunzio, Marcus Watkins, Pallawi Torka, Reem Karmali, Andrea Anampa-Guzmán, Timothy S. Oh, Heather Reves, Montreh Tavakkoli, Emily Hansinger, Beth Christian, Colin Thomas, Stefan K. Barta, Praveen Ramakrishnan Geethakumari, Nancy L. Bartlett, Geoffrey Shouse, Adam J. Olszewski, Narendranath Epperla

Get full text

Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers by Timothy J. Voorhees, Eric M. McLaughlin, Pallawi Torka, Jorge Florindez, Na Hyun Kim, Tamara K. Moyo, Heather Reves, Nuttavut Sumransub, Saarang Deshpande, Ashley Rose, Cassandra Duarte, Muhammad Salman Faisal, Showkat Hamid, Suki Subbiah, Sabarish Ayyappan, Lauren Shea, Matt Cortese, Krish Patel, Ajay Major, Hayder Saeed, Jakub Svoboda, Sanjal Desai, Praveen Ramakrishnan Geethakumari, Mehdi Hamadani, Natalie Grover, Narendranath Epperla

Get full text

Outcomes of follicular lymphoma with leukemic phase in the modern era: results from a large multicenter study by Asaad Trabolsi, Sunwoo Han, Narendranath Epperla, Kaitlin Annunzio, Firas Baidoun, Muhamad Alhaj Moustafa, Dan Morgenstern-Kaplan, Peter Doukas, Frederique St-Pierre, Brittany McCall, Lindsey Fitzgerald, Jose Sandoval-Sus, Shivani Dalal, Isildinha M. Reis, Jennifer Rose Chapman-Fredricks, Seo-Hyun Kim, Cherry Au, Natalie B. Otto, Khaled Alhamad, Thomas Ollila, Reem Karmali, Geoffrey Shouse, Izidore S. Lossos, Juan Pablo Alderuccio

Get full text

Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapy by Reem Karmali, Geoffrey Shouse, Pallawi Torka, Tamara K. Moyo, Jason Romancik, Stefan K. Barta, Rahul Bhansali, Jonathon B. Cohen, Nirav N. Shah, Joanna Zurko, Vaishalee P. Kenkre, Brian Hess, Deborah M. Stephens, Lindsey Fitzgerald, Thomas Ollila, Bukky Tabiti, Ishan Roy, Shuo Ma, Jane Winter, Barbara Pro, Jonathan Moreira, Alexey V. Danilov, Kevin David, Leo I. Gordon, Narendranath Epperla

Get full text

Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies by Elvira Umyarova, Charles Pei, William Pellegrino, Qiuhong Zhao, Nidhi Sharma, Don Benson, Francesca Cottini, Evandro Bezerra, Jonathan Brammer, Naresh Bumma, Hannah Choe, Nathan Denlinger, Srinivas Devarakonda, Abdullah Khan, Sam Penza, Ashley Rosko, Sumithira Vasu, Sarah Wall, Lapo Alinari, Robert Baiocchi, David A. Bond, Beth Christian, Walter Hanel, Kami Maddocks, John Reneau, Yazeed Sawalha, Alma Habib, Audrey Sigmund, Timothy J. Voorhees, Marcos de Lima, Narendranath Epperla

Get full text